Analytical Data
-
Gene name
GEMIN6
- Application
-
Alternative Names
GEMIN6;Gem-associated Protein 6
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8WXD5
-
Expression Region
1-167aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSMSEWMKK GPLEWQDYIY KEVRVTASEK NEYKGWVLTT DPVSANIVLV NFLEDGSMSV TGIMGHAVQT VETMNEGDHR VREKLMHLFT SGDCKAYSPE DLEERKNSLK KWLEKNHIPI TEQGDAPRTL CVAGVLTIDP PYGPENCSSS NEIILSRVQD LIEGHLTASQ
-
Molecular Weight
22 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GEMIN6 is a key component of the survival of motor neuron (SMN) complex, which plays a crucial role in the biogenesis and assembly of small nuclear ribonucleoproteins (snRNPs) essential for pre-mRNA splicing. Research into GEMIN6 has gained significant attention due to its involvement in spinal muscular atrophy (SMA), a severe genetic disorder characterized by the degeneration of motor neurons leading to muscle atrophy and weakness. The SMN complex, of which GEMIN6 is an integral part, is essential for the assembly and stability of snRNPs, which are vital for the splicing of pre-mRNA, thus directly impacting gene expression regulation. Studies have demonstrated that reduced levels of SMN protein, and consequently GEMIN6, contribute to the pathophysiology of SMA. Understanding the structural and functional characteristics of GEMIN6 and its interactions within the SMN complex is crucial for developing targeted therapies. Recent advances in protein expression and purification techniques have facilitated research into GEMIN6, enabling detailed analyses of its role in snRNP assembly and function. Additionally, investigating GEMIN6's potential as a therapeutic target offers hope for the development of innovative treatments that could ameliorate the symptoms of SMA and improve the quality of life for affected individuals. Ultimately, research on GEMIN6 not only deepens our understanding of the molecular mechanisms underlying SMA but also paves the way for novel therapeutic strategies aimed at restoring normal splicing processes in affected patients.
